Almost 400 researchers signed the petition to promote the adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025.
The VPH Institute together with the Avicenna Alliance, the Insigneo Institute for in silico Medicine and the Alma Mater Studiorum, University of Bologna has opened a petition to recommend EMA to include in the their strategy plan a more articulated role for in silico technologies.
The EMA proposed strategy recognizes the importance of emerging technologies in general and modelling and simulation, also known as in silico methods, in particular. However, the document tends to stress the value of in silico methods almost exclusively in connection with the reduction of animal experimentation. While we agree that this is a relevant application for such methods, it is not the only one and likely not the most impactful one for the patient and for the industry. The term In Silico Trials indicates a number of use cases, not only related to pre-clinical evaluation, but also to the reduction, refinement, and in some cases even replacement of clinical trials
Full details can be found here: https://www.change.org/p/guido-rasi-foster-adoption-of-in-silico-trials-through-ema-s-strategy-on-regulatory-science-to-2025
So far the petition has been signed by almost 400 researchers, and our recommendations have now been sent to Professor Guido Rasi, the Director of EMA to bring his attention to the issue.
We will keep you posted on the future developments. In the meantime, in case you still have not done it, please make sure to sign the petition, which is still currently open.